Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients. The primary purpose of this study is to evaluate the efficacy of 177Lu-LNC1004 Injection in patients with FAP-positive RAIR-DTC who have failed first-line TKIs treatment or refuse standard treatment. All subjects will receive 80 mCi (± 10%) 177Lu-LNC1004 Injection intravenously every 6 weeks for 2 cycles.

Trial Details

NCT ID
NCT06898437
Phase
EARLY_PHASE1
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • 177Lu-LNC1004 Injection
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Subject must have the ability to understand and sign an approved informed consent form (ICF).
  • Aged 18 years or older, regardless of sex.
  • Histologically or cytologically confirmed RAIR-DTC subject who has failed TKIs treatment or refuse standard therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →